Sarepta Advances Precision Genetic Therapies Toward Full FDA Approval: AMONDYS 45 and VYONDYS 53 Seek Traditional Approval Status
Sarepta Therapeutics has announced a significant regulatory milestone in its efforts to secure permanent FDA approval for two breakthrough Duchenne muscular dystrophy (DMD) treatments. As reported by BusinesWire.com, the company…